Alpha 2.0
Login Register
» Authors » M J Holtkamp

M J Holtkamp

Explore the profile of M J Holtkamp including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 67
Followers 0
Related Specialties
Oncology
Nursing
General Surgery
Top 10 Co-Authors
S Rodenhuis
J W Baars
J H Schornagel
E van der Wall
W J Nooijen
O Dalesio
D J Richel
C E van der Schoot
J H Beijnen
J G Schrama
Published In
Br J Cancer
Ann Oncol
Anticancer Res
Eur J Cancer Care (Engl)
J Clin Apher
Affiliations
Soon will be listed here.
Recent Articles
1.
Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study
van Ommen-Nijhof A, Steenbruggen T, Wiersma T, Balduzzi S, Daletzakis A, Holtkamp M, et al.
Eur J Cancer . 2024 Nov; 213:115083. PMID: 39489924
Background: Oligometastatic breast cancer (OMBC) is a clinical entity with a prospect of long-term survival, but uncertainty remains on its optimal treatment. We studied whether intensified alkylating chemotherapy (IACT) improves...
2.
The effectiveness of chlorhexidine-silver sulfadiazine impregnated central venous catheters in patients receiving high-dose chemotherapy followed by peripheral stem cell transplantation
Maaskant J, de Boer J, Dalesio O, Holtkamp M, Lucas C
Eur J Cancer Care (Engl) . 2009 May; 18(5):477-82. PMID: 19453696
Immuno-compromised patients are at high risk for all kind of infections. Unfortunately, they need central venous catheters (CVCs), which are associated with infectious complications. In this study we examined the...
3.
Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience
Schrama J, Holtkamp M, Baars J, Schornagel J, Rodenhuis S
Br J Cancer . 2003 Jun; 88(12):1831-8. PMID: 12799623
High-dose chemotherapy (HD-CT) has a role in the potentially curative treatment of several tumours. The relative efficacies of the different regimens have not been studied in comparative trials, but it...
4.
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin
Huitema A, Spaander M, Mathjt R, Tibben M, Holtkamp M, Beijnen J, et al.
Ann Oncol . 2002 May; 13(3):374-84. PMID: 11996467
Background: High-dose chemotherapy in combination with peripheral blood progenitor cell transplantation is widely used in the treatment of several malignancies. The use of high-dose chemotherapy can be complicated by the...
5.
Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer
Schrama J, Baars J, Holtkamp M, Schornagel J, Beijnen J, Rodenhuis S
Bone Marrow Transplant . 2001 Aug; 28(2):173-80. PMID: 11509935
The purpose of this study was to determine the feasibility and efficacy of multiple courses of high-dose cyclophosphamide, carboplatin and thiotepa with peripheral blood progenitor cell (PBPC) transplantation in women...
6.
Adjustment of the interface detector (location 71) to the absolute number of mononuclear cells in the peripheral blood: no improvement of the collection efficiency of the Fenwal CS3000 plus during progenitor cell harvests
Baars J, Nooyen W, van Beers C, Holtkamp M, Te Velde A, Daleslo O, et al.
J Clin Apher . 1997 Jan; 12(2):68-73. PMID: 9263113
Improvement of the collection efficiency (CE) of the Fenwal CS3000 plus in collecting circulating progenitor cells (CPC) might diminish the number of leukapheresis procedures (LP) required to obtain the CPC...
7.
Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours
Baars J, Holtkamp M, Nooyen W, Walll E, Te Velde A, Dalesio O, et al.
Anticancer Res . 1996 Sep; 16(5B):3089-95. PMID: 8920773
The mobilisation characteristics of ifosfamide and etoposide followed by Granulocyte Colony-Stimulating Factor fGCSF, filgrastim) were analysed in 17 patients with malignant lymphoma and 24 patients with solid tumours, with respect...
8.
Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients
van der Wall E, Rutgers E, Holtkamp M, Baars J, Schornagel J, Peterse J, et al.
Br J Cancer . 1996 May; 73(9):1080-5. PMID: 8624267
The prognosis of patients with stage IIIB breast carcinoma with tumour spread to the apical axillary lymph nodes has hardly improved despite adequate locoregional control and the introduction of systemic...
9.
Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer
Rodenhuis S, Westermann A, Holtkamp M, Nooijen W, Baars J, van der Wall E, et al.
J Clin Oncol . 1996 May; 14(5):1473-83. PMID: 8622061
Purpose: To determine the feasibility and safety of multiple, closely timed courses of high-dose cyclophosphamide, thiotepa, and carboplatin (CTC) with peripheral-blood progenitor-cell transplantation (PBPCT). Patients And Methods: Forty-eight patients with...
10.
High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach
van der Wall E, Nooijen W, Baars J, Holtkamp M, Schorangel J, Richel D, et al.
Br J Cancer . 1995 Apr; 71(4):857-62. PMID: 7536025
In 29 chemotherapy-naive patients with stage II-III breast cancer, peripheral blood stem cells (PBSCs) were mobilised following fluorouracil 500 mg m-2, epirubicin 90-120 mg m-2 and cyclophosphamide 500 mg m-2...